{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:38:13Z","timestamp":1770136693253,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Grant. 2023JCYBJC01800, Grant. 23JCZDJC01200"],"award-info":[{"award-number":["Grant. 2023JCYBJC01800, Grant. 23JCZDJC01200"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004945","name":"Nankai University","doi-asserted-by":"publisher","award":["Grant. NKTM2023004"],"award-info":[{"award-number":["Grant. NKTM2023004"]}],"id":[{"id":"10.13039\/501100004945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Acute graft-versus-host disease (aGVHD) after liver transplantation (LT) is a rare but highly lethal complication, with no standardized diagnosis\/treatment protocols. Our center successfully treated three patients using a comprehensive antithymocyte globulin (ATG)-based regimen. This study preliminarily evaluates the efficacy of ATG-based regimens for aGVHD, comparing outcomes with a historical cohort that received conventional treatment, to provide initial clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included three consecutive post allogeneic LT aGVHD patients treated at Tianjin First Central Hospital between January 2024 and August 2025. Their outcomes were compared with those of 10 historical controls who received conventional treatment between January 2019 and December 2023. Given the small sample size, outcomes were primarily compared descriptively and using effect size measures (odds ratio [OR]\/median difference), while Fisher\u2019s exact and Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      tests were performed for exploratory purposes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the ATG treatment group, two patients presented with fever and rash, while one presented with diarrhea; all developed skin involvement, oral ulcers, and myelosuppression, with a median posttransplant onset of 18 days (range: 15\u201327). Skin biopsy revealed epidermal hyperkeratosis, basal cell vacuolar degeneration, and dermal lymphocytic infiltration. Cases 2 and 3 had donor CD8+ T-cell chimerism. Median onset-to-diagnosis time was 15 days (range: 9\u201317). Treatment included an ATG-based regimen, tacrolimus tapering\/withdrawal, low-dose glucocorticoids, intravenous immunoglobulin (IVIG), janus kinase (JAK) inhibitor (ruxolitinib), and symptomatic supportive care. All three patients achieved complete remission (CR) without serious complications, with a median diagnosis-to-remission time of 35 days (range: 17\u201350). In this preliminary comparison, the ATG group demonstrated a significantly higher CR rate (100%\n                      <jats:italic>vs<\/jats:italic>\n                      . 20%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.012, OR = 25.0), a lower infection rate (0%\n                      <jats:italic>vs<\/jats:italic>\n                      . 60%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.033), and a shorter median remission time (35 days\n                      <jats:italic>vs<\/jats:italic>\n                      . 62 days;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.021, median difference = \u2212 27 days) compared with historical controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The diagnosis of aGVHD after LT requires integrating clinical manifestations, rash pathology, and chimerism detection. In this small series, ATG-based therapy was associated with favorable outcomes compared with a historical cohort receiving conventional therapy, suggesting that it may be a promising strategy warranting further evaluation in large-scale clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1696936","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:21:52Z","timestamp":1770096112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective treatment of acute graft-versus-host disease following liver transplantation using an integrated regimen centered on antithymocyte globulin: a single-center experience"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiming","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ababakri","family":"Abdisamat","sequence":"additional","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of General Surgery\/Transplantation, First Central Hospital of Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Liver Transplantation, Tianjin First Central Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital","place":["Tianjin, China"]},{"name":"Tianjin Key Laboratory for Organ Transplantation, Tianjin First Center Hospital","place":["Tianjin, China"]},{"name":"Institute of Transplantation Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i37.5240","article-title":"Graft-versus-host disease after liver transplantation: a comprehensive literature review","volume":"18","author":"Akbulut","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0260","DOI":"10.1097\/HC9.0000000000000260","article-title":"Graft-versus-host disease following liver transplantation: A systematic review of literature","volume":"7","author":"Kneifel","year":"2023","journal-title":"Hepatol Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015954","article-title":"How I diagnose and treat acute graft-versus-host disease after solid organ transplantation","volume":"141","author":"Cooper","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.716","article-title":"Fluorescent in situ hybridization of a skin biopsy: an adjunctive tool to support a diagnosis of graft-versus-host disease","volume":"64","author":"Nguyen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MEG.0000000000001530","article-title":"Graft-versus-host disease after living donor liver transplantation: an unpredictable troublesome complication for liver transplant centers","volume":"32","author":"Gonultas","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003607","article-title":"Incidence and risk factors for fatal graft-versus-host disease after liver transplantation","volume":"105","author":"Kitajima","year":"2021","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26320","article-title":"Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current concepts and advances in graft-versus-host disease immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840140212","article-title":"Graft vs. host disease after liver transplantation in humans: a report of four cases","volume":"14","author":"Roberts","year":"1991","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00406.x","article-title":"Acute graft versus host disease following liver transplantation: the enemy within","volume":"4","author":"Taylor","year":"2004","journal-title":"Am J Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000952","article-title":"Cytokines and costimulation in acute graft-versus-host disease","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21082","article-title":"Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients","volume":"13","author":"Chan","year":"2007","journal-title":"Liver Transpl"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41030419.x","article-title":"Microchimerism, GVHD, and tolerance in solid organ transplantation","volume":"41","author":"Triulzi","year":"2001","journal-title":"Transfusion"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaad.2017.12.050","article-title":"Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1145056","article-title":"Immunological basis for treatment of graft versus host disease after liver transplant","volume":"12","author":"Rai","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1590\/s1807-59322011000600035","article-title":"Graft-versus-host disease after liver transplantation","volume":"66","author":"Chaib","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajh.27593","article-title":"Toward improving initial therapy of acute graft versus host disease","author":"Mehta","year":"2025","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.03.009","article-title":"Acute graft versus host disease following liver transplantation: case report with review of current literature","volume":"12","author":"Renganathan","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2017.0231","article-title":"Early use of etanercept for graft-versus-host disease after liver transplant: the importance of broad spectrum infective prophylaxis","volume":"18","author":"Boscolo","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1058739","article-title":"Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients","volume":"13","author":"Storci","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030382","article-title":"Antithymocyte globulin inhibits CD8+ T cell effector functions via the paracrine induction of PDL-1 on monocytes","volume":"12","author":"Copic","year":"2023","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15579","article-title":"The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation","volume":"20","author":"Jacobs","year":"2020","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2014.06.061","article-title":"Abatacept use in graft-versus-host disease after orthotopic liver transplantation: a case report","volume":"46","author":"Elfeki","year":"2014","journal-title":"Transplant Proc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jtct.2021.08.031","article-title":"Planned granulocyte colony-stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with thymoglobulin for myeloid Malignancy","volume":"27","author":"Orfali","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.009","article-title":"Graft-versus-host disease causes broad suppression of hematopoietic primitive cells and blocks megakaryocyte differentiation in a murine model","volume":"20","author":"Lin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.03.007","article-title":"Immunosuppression withdrawal in living-donor renal transplant recipients following induction with antithymocyte globulin and rituximab: Results of a prospective clinical trial","volume":"24","author":"Markmann","year":"2024","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2022.186","article-title":"Parvovirus B19-associated severe anemia in adult liver transplant recipients: A case series and review of the literature","volume":"23","author":"Cheng","year":"2022","journal-title":"Surg Infect (Larchmt)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.01.015","article-title":"Posttransplant lymphoproliferative disorder following kidney transplantation: A review","volume":"78","author":"Sprangers","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.025","article-title":"In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder","volume":"102","author":"Thieme","year":"2022","journal-title":"Kidney Int"},{"key":"B31","first-page":"aaf8759","article-title":"Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation","volume-title":"Sci Immunol","author":"Marino","year":"2016"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13843","DOI":"10.1111\/tid.13843","article-title":"Infectious complications in acute graft-versus-host disease after liver transplantation","volume":"24","author":"Chesdachai","year":"2022","journal-title":"Transpl Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:21:53Z","timestamp":1770096113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1696936"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1696936","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1696936"}}